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Abstract
Background: Several factors have been identified as being associated with increased adherence to antiretroviral
therapy, including sero-status disclosure; however, studies examining the effect of disclosure on ART adherence in
Ethiopia have had inconsistent findings. This systematic review and meta-analysis therefore aims to estimate the
pooled effect of disclosure on adherence to ART among adults living with HIV in Ethiopia.
Methods: We performed a systematic search for articles reporting on peer-reviewed, quantitative, English-language
observational studies of reporting the association between self sero-status disclosure and good ART adherence in
adults living with HIV/AIDS in Ethiopia during published from 2010 to 2015. We searched four electronic databases:
PubMed/Medline, the World Health Organization’s Hinari portal (which includes the SCOPUS, African Index Medicus,
and African Journals Online databases) for studies from December 1, 2017 to January 30, 2018. We also searched
university repositories and conference abstracts for unpublished studies. We conducted a meta-analysis for the
pooled effect of adherence using a random effects model in Stata version 14 and assessed publication bias using
the Egger’s test for funnel plot asymmetry.
Results: Our search returned in 179 studies, of which seven (3.9%), were eligible and included in the final
meta-analysis. The seven included studies were conducted from 2010 to 2015. Our analysis found that disclosure
had a significant effect on the adherence to ART in adult patients living with HIV. Patients who disclosed were 1.64
times more likely to have good adherence to ART compared with those who did not (OR: 1.64, 95% CI: 1.11, 2.42).
The small number of studies eligible for review and differences in study definitions of adherence and disclosure
were the main limitations of this study.
Conclusion: This review found a statistically significant positive effect of disclosure status on the adherence to ART
in adult patients living with HIV in Ethiopia. This suggests that Ethiopia’s national treatment and prevention
programs should redouble efforts to encourage self-disclosure among people living with HIV/AIDS. Encouraging
supportive social environments for disclosure, and promoting partner notification and partner disclosure support
initiatives might be particularly helpful in this regard.
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Background
The unprecedented global response to the HIV/AIDS pan-
demic of the 1990s brought millions of people living with
HIV/AIDS (PLWHA) access to lifesaving antiretroviral ther-
apy (ART). The success of these programs and the continu-
ing challenges in developing and implementing effective
HIV prevention interventions have meant that the number
of people receiving ART has continued to grow steadily. It
is estimated that 21.7 million people worldwide were receiv-
ing ART by the end of 2017 [1]. In the region of the world
most heavily affected by HIV/AIDS—eastern and southern
Africa—UNAIDS estimates that 65% of PLWHA are receiv-
ing ART [2]; in Ethiopia, 75% of adult PLWHA (approxi-
mately 415,578 people) were receiving ART in 2017 [2].
While the growth of ART treatment programs in sub-
Saharan Africa is impressive, these programs are fragile:
heavily reliant on a few, low-cost ART drug regimens pri-
marily financed by external donors [3]. High levels of pa-
tient adherence to ART (e.g., 95% of doses taken), crucial
for maintaining the health of PLWHA, have become even
more important in this context of limited antiretroviral drug
choice, as adherence is crucial for preventing resistance to
these drugs. Unfortunately, maintaining good patient adher-
ence to ART in these programs continues to be challenging.
Studies in low-income countries have identified several
factors that affect adherence to ART, of which disclosure
of patient sero-status is a major contributing factor [4–7].
Social support, access to mental health care, counseling,
educational interventions, and good nutrition have also
been found to be associated with increased adherence to
ART [4–7]. Treatment factors such as the complexity of
the drug regimen and provider factors such as the quality
of relationships between providers and patients have also
been found to influence adherence rates [8–10].
The disclosure of one’s HIV status to relatives, friends,
and sexual partners has significant health implications.
Studies have found that patients who disclosed their sero-
status had better social support; stronger family and rela-
tionship cohesion; reductions in anxiety and depression;
improvements in physical health, emotional support, and
financial support; and were better able to take ART freely
and to improve their ART adherence [11–13]. Conversely,
high levels of employment discrimination, fear of being
abandoned by family members, fear of divorce, and com-
munication difficulties were the most important barriers
to disclosing sero-status [11, 14–16].
While the relationship between disclosure and adherence
is fairly well-established in high-income settings, fewer
studies have investigated the association in sub-Saharan Af-
rica. Studies that have examined the association between
ART adherence and disclosure among PLWHA in Ethiopia
in particular have presented inconsistent results, with some
finding strong positive associations and others finding lim-
ited or even negative associations between the two factors
[17, 18]. The one existing systematic review of factors re-
lated to adherence in sub-Saharan Africa included only a
handful of articles that examined the effect of disclosure
specifically [6].
This systematic review and meta-analysis seeks to fill
the gaps in the Ethiopian literature by estimating the
pooled effect of disclosure status on adherence to ART
among adult patients living with HIV in Ethiopia. Un-
derstanding Ethiopia’s specific adherence challenges is
important, as the country has a large national ART treat-
ment program serving extremely heterogeneous geo-
graphic regions and socio-economic groups. Although
the country’s overall adult HIV prevalence has declined
significantly in the last two decades [19], the epidemic is
spread among the adult population with large geo-
graphic and sub-population variation in prevalence and
important regional hotspots with very high prevalence
occurring in large urban areas and certain regions such
as Gambella [20]. Determining whether the impact of
disclosure on adherence is as strong in Ethiopia as in
other settings, or whether is there are regional or sub-
population variation in the importance of disclosure
might, therefore, be useful for policy makers trying to
determine the amount of resources to dedicate to dis-
closure promotion activities. Being efficient in HIV pro-
gram resource allocation is particularly important as
Ethiopia continues to expand its national program to
rural areas while shifting donor priorities and institu-
tional changes [3, 21]. We hope that our findings will be
useful to these stakeholders who are interested in de-
signing appropriate interventions to improve ART adher-
ence and sero-status disclosure among PLWHA.
Methods
We conducted this systematic review and meta-analysis per
PRISMA guidelines [22]. This study was not pre-registered.
Eligibility criteria, data sources and search strategy
We performed our electronic database search using
PubMed/MEDLINE, Hinari (a World Health Organization
sponsored database that provides low-income researchers
access to the SCOPUS, African Index Medicus, and African
Journals Online databases), Google Scholar, and the
Cochrane Library.
We built a search strategy by using the Boolean operator
“and/or” with combinations of keywords. For example, (“ad-
herence” AND “antiretroviral” AND “association” OR “de-
terminant” AND “disclosure” AND “therapy” AND
“Ethiopia”). For PubMed’s advance search, we used Medical
Subject Headings (MeSH terms, See Appendix) to expand
the search strategy. Unpublished studies were also accessed
through the Addis Ababa University library. The reference
lists of included studies were also reviewed to retrieve add-
itional studies. The Cochrane library was explored in an
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effort to confirm whether there were existing systematic re-
views or meta-analyses and to check the availability of on-
going projects related to the current systematic review and
meta-analysis.
Eligible publications were peer reviewed, English-
language scholarly articles or PhD dissertations, and peer
reviewed conference abstracts published between the
years 2010 to 2015; for observational, quantitative stud-
ies that took place in Ethiopia; and that investigated the
association between sero-status disclosure and adher-
ence to ART among adults (age 18 years and greater) liv-
ing with HIV and currently receiving antiretroviral
therapy. We excluded the studies focusing on children,
review articles, and articles that had methodological
problems after being reviewed by two authors using the
Newcastle-Ottawa Scale (NOS) criteria [23].
Data abstraction and quality assessment
Two reviewers screened the abstracts and titles of arti-
cles found by the search for relevance and for match
with our inclusion criteria. When it was unclear whether
an abstract was relevant or not, it was included for re-
trieval. The two reviewers then retrieved the full text of
the screened articles then assessed them for relevance
based on their topic, study outcomes, and methodology.
Articles deemed irrelevant to the study were removed at
this stage and the full text of the remaining articles
reviewed for quality, by two study investigators using the
Newcastle-Ottawa Scale (NOS). Articles whose NOS
quality scores were less than an average score of six by
the two investigators were excluded from the final ana-
lysis. Discrepancies were resolved with a third reviewer
whenever appropriate.
Data analysis and synthesis
Data were extracted from each of the original studies
using Microsoft Excel and Stata version 14 for further
analysis. Heterogeneity was checked by using an I2 test
statistic [24]. We used a forest plot to visualize the pres-
ence of heterogeneity. Since there was relatively moder-
ate heterogeneity, we used a random effects model for
analysis to estimate the pooled effect. We also used fun-
nel plot asymmetry and Egger’s test of the intercept to
check for publication bias. [25]. To verify the results,
two researchers independently computed the main stat-
istical analyses and checked for consistency. The effect
size estimates were converted to odds ratios, as all in-
cluded studies compared two groups and reported di-
chotomous outcomes.
Results
Selection and identification of original studies
Our search identified 179 published articles, of which 148
articles were found in the PubMed, Hinari and Scholar
databases; the remaining were found in university librar-
ies, conference abstracts, or reference lists (see Fig. 1). Of
the total identified, 154 articles were excluded at initial as-
sessment after reviewing their titles based on the inclusion
criteria. The abstracts and full text of the remaining 25
studies were assessed and screened for eligibility criteria
and whether they reported the outcome variable of inter-
est (adherence); 18 articles were excluded due to failure to
meet inclusion criteria. Two articles were excluded due to
poor quality based on the selection criteria [17, 26]. Four
articles were excluded because their regression tables did
not include disclosure as an independent variable [27–30].
Two articles were excluded because their results did not
report odds ratios or statistics that could be converted
into odds ratios [31, 32]. Seven studies met the eligibility
and quality criteria and were included in the analysis.
Study measures
For the purpose of this review, we allowed the broadest def-
inition of “disclosure” employed by the studies under review,
defining it as disclosure to community members (inclusive
of family, religious leaders, friends etc.). We also the broad-
est definition of “good adherence” employed by the studies
under review: defining it as fewer than three missed doses
per day over the study period. Table 1 below lists how each
of the seven included studies defined disclosure and good
adherence. Our principal summary measure was odds of
“good adherence”, i.e., an odds ratio either directly reported
or calculated from the study outcomes presented.
Characteristics of included studies
The seven studies included in the review were all cross-
sectional [18, 33–38]. They had a total of sample of 2260
adults living with HIV/AIDs in Ethiopia and were con-
ducted from 2010 to 2015 in various regions of the
country. The study sample sizes ranged from 233 to 422
participants [36, 38]. Of the seven studies included in
the final analysis, three were conducted in the Amhara
region [18, 34, 36] and two were conducted in the
Southern Nations Nationalities and People (SNNPR) re-
gion [33, 35]. The remaining two studies were conducted
in Oromia [38] and Harari regions [37] respectively.
The highest odds ratio (OR) for impact of sero-status
disclosure on adherence was 3.41, reported for a study
conducted in Oromia region [38]. The smallest odds ratio
for sero-status disclosure (0.84) was reported in study
conducted in Amhara region [34]. The latter study was
the only study included which reported an OR below 1 (or
a negative impact of disclosure on adherence). Although it
went unmentioned by the study authors, lack of social
support and its negative impact on both adherence and
disclosure is well understood in the literature [39].
All included studies were conducted within a hospital
or clinic environment. Geographically, they spanned
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Fig. 1 PRISMA Flow diagram showing the procedure of selecting studies for meta-analysis, 2010–2015, Ethiopia













1 Mitiku et al.
[37]
2013 Harari 239 > 95% of prescribed ARV drugs for the
past 7 days.
Family or others 164/208 44/208 1.09
2 Mohammed
et al. [38]
2015 Oromia 237 < 3 missed doses/day over study
period
Community 175/197 22/197 3.41
3 Ketema et al.
[36]
2015 Amhara 422 0 missed dose during the 30-day





4 Alagaw et al.
[33]





5 Tsega et al.
[18]
2015 Amhara 351 < 3 missed doses over the entire time
of therapy (Range: >6mo to < 3 yr)
Family 265/284 19/284 1.13
6 Gelan [35] 2010 SNNPR 277 Patients who reported an intake of





7 Asmare et al.
[34]
2014 Amhara 377 < 3 missed doses per month Family/Relatives 37/55 18/55 0.85
Note: all studies were cross-sectional
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three of the most populous regions in Ethiopia and con-
tained a mix of both rural and urban populations.
The effect of disclosure on adult antiretroviral therapy
adherence
We found significant heterogeneity across studies (I2 =
42.9%, p = 0.105), which means that using a fixed effects
model would have led to an unreliable estimate. There-
fore, we used a random effects model to estimate the
pooled effect of disclosure on the adherence reported by
the seven studies with inverse variance. We found no
evidence of publication bias after using a funnel plot of
asymmetry and Egger’s test. Although visual examination
of the funnel plot shows it to be asymmetric, Egger’s test
of the intercept (B0) was 0.47 (95% CI: − 5.16, 6.11 p = 0.
0.28) (see Fig. 2).
Our meta-analysis found that sero-status disclosure
had statistically significant effects on adherence to ART.
Adults living with HIV who disclosed their sero-status
were 1.64 times more likely to have good adherence
compared to patients who did not disclose (OR: 1.64,
95% CI: 1.11, 2.42).
Discussion
This systemic review and meta-analysis attempted to esti-
mate the pooled effect of disclosure on adherence to ART
among adults living with HIV in Ethiopia. Our analysis in-
dicated that disclosure of sero-status had a statistically sig-
nificant effect on adherence to ART. The odds of having
good adherence among adults living with HIV who dis-
closed their sero-status were 64% higher than those who
did not disclose their sero-status with (OR = 1.64 (95% CI:
1.11, 2.42)). The positive relationship between HIV dis-
closure status and adherence to ART in our analysis is
consistent with the findings of primary studies and re-
views conducted in high income settings, that found that
HIV status disclosure was strongly correlated with ART
drug adherence [40–42]. Our results are also in line with
those from a systematic review of factors associated with
adherence in sub-Saharan Africa, which found that dis-
closure among people living with HIV had a positive effect
on ART adherence (OR = 3.46; 95% CI 2.04 to 5.89) [6].
Our estimated pooled odds ratios are more modest than
the odds reported in the sub-Saharan Africa systematic re-
view, reflecting perhaps the small number of studies that
we had under review and the heterogeneity in the defini-
tions of the independent and dependent variables. An-
other possible explanation may be that the positive impact
of disclosure in Ethiopia is dampened (or reversed in the
case of the study which found that it has negative impact)
by a lack of social support in the country. Self-disclosure
by itself does not improve adherence. Rather, one of the
reasons that self-disclosure is important is that it helps
PLWHA to ask for and receive crucial social support and,
and, this in turn promotes better mental health and good
ART adherence [39, 43]. In contrast, depression and poor
social support have been show to negatively affect ART
drug adherence [6, 44]. The relationship between social
support and disclosure may be bi-directional in that poor
social support may preclude disclosure if PLWHA do not
feel safe in sharing their status. The literature and the
studies included in our review suggest that the relation-
ships between poor adherence and disclosure might be ex-
plained, in part, by inadequate social support leading to
Fig. 2 Forest plot of studies on the effect of disclosure on ART adherence among adult HIV patients, 2010–2015, Ethiopia
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fear of taking drugs in front of family members; this is
then leads patients to hide their sero-status from relatives,
making it difficult to take medication at a prescribed time
[45]. This suggests that programs to create supportive en-
vironments in which people feel safe to disclose, might
have more of an impact on adherence than promoting dis-
closure on its own. Promoting support from key, highly
respected parties such religious leaders, and providing
counseling support for disclosure between couples and
with relatives (rather than promoting disclosure to any-
one) may be particularly important.
Our review adds to the literature by aggregating and
highlighting articles germane to Ethiopian experiences.
Ethiopia’s HIV epidemic is different than other epidemics
in the region in that it is widely spread across the country,
it is highly concentrated in certain geographic regions and
in specific vulnerable populations. The country also has
unique religious and socio-political structures in the Ethi-
opian Orthodox Church and the Gada System of the
Oromo for example, which have the potential to influence
the level of social support for PLWHA and their ability to
disclose their HIV status. In addition, care-seeking behav-
ior in Ethiopia is idiosyncratic, with its own traditions of
alternative medicines and treatments such as the extensive
use of holy water, among other things [36, 38, 46]. The
use of these alternative treatments may also influence ad-
herence and disclosure.
While many HIV prevention strategies are transferrable
across settings, it is critical to have country-specific cultur-
ally relevant solutions for HIV prevention and treatment.
Country-specific studies such as ours, aid in the develop-
ment of these solutions. Our findings coupled with that
from the literature, underscore the importance of active
self-disclosure of sero-status and may serve as an import-
ant reminder for policy makers and program planners to
strengthen existing strategies and explore novel or more
aggressive strategies such as partner notification to sup-
port PLWHA to take this difficult step.
Limitations
There are several limitations to this study. First our search
yielded only a modest number of articles to review. Sec-
ond, our findings were the pooled effect of many cross-
sectional study designs, which are limited in their ability
to draw upon causal inferences. The small number of
studies included in the review and the patchiness of the
data on respondent characteristics that they reported also
limited our ability to conduct sub-group analyses of the
studies in order to better explain the heterogeneity of the
studies. Another important limitation is that the articles
reviewed came primarily from smaller journals where the
extent of peer review was difficult to assess, or from non-
peer reviewed dissertations. In addition, although we
followed standard PRISMA protocols, we must note that
our study was not pre-registered. Finally, and most import-
ant, the studies that we reviewed lacked of standardized
definitions for both good adherence and disclosure which
may have increased the heterogeneity of our findings.
Conclusion
Our systematic review and meta-analysis demonstrated
that disclosure of HIV sero-status had a statistically sig-
nificant positive effect on adherence to ART among
adults living with HIV in Ethiopia. This suggests that
Ethiopia’s national treatment and prevention programs
should redouble efforts to encourage self-disclosure
among people living with HIV/AIDS. Partner notifica-
tion and partner disclosure support initiatives might be
particularly helpful in this regard. Counseling guidelines
for health professionals who work in HIV treatment and
testing should emphasize discussing disclosure with pa-
tients. Future research should focus on documenting the
ART support needs of priority vulnerable adult popula-
tions in Ethiopia especially sex workers, seasonal la-
borers, women, and men who have sex with men and
determining the factors hinders them from disclosing
and adhering to ART in order to identify solutions for
managing their care compassionately and effectively.
Appendix
PubMed Advanced Search Terms
(((((adherence[All Fields] AND (“anti-retroviral agent-
s”[Pharmacological Action] OR “anti-retroviral agents”[-
MeSH Terms] OR (“anti-retroviral”[All Fields] AND
“agents”[All Fields]) OR “anti-retroviral agents”[All Fields]
OR “antiretroviral”[All Fields])) AND (“association”[MeSH
Terms] OR “association”[All Fields])) OR (“association”[-
MeSH Terms] OR “association”[All Fields])) AND (“disclo-
sure”[MeSH Terms] OR “disclosure”[All Fields])) AND
(“therapy”[Subheading] OR “therapy”[All Fields] OR “thera-
peutics”[MeSH Terms] OR “therapeutics”[All Fields]))
AND (“ethiopia”[MeSH Terms] OR “ethiopia”[All Fields])
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